JUN 15, 2021 7:00 AM PDT

Enabling biomarker discovery with functional proteomics

SPONSORED BY: IsoPlexis

Clinical biomarkers are critical for the acceleration of curative medicines. The identification of these novel clinical biomarkers allows researchers to better understand complex mechanisms of immune response to diseases, facilitating the development of more effective therapeutics. Functional biomarkers can be used to predict response, identify potential effective treatments, and monitor a patient's response to treatment. Functional biomarker discovery is leading the growth of personalized medicine, allowing researchers and clinicians to tailor treatment to a patient's individual immune profile. 

With scientists conducting groundbreaking research every day to gain insight into the world's most complex and life-threatening diseases and bring effective treatments to patients around the globe, the need to get answers faster and accelerate therapeutic development timelines is more urgent than ever. Functional proteomics is one of the most promising fields for the development of life-saving vaccines and therapeutics and the ability to conduct multi-omic analysis is also crucial, as it enables scientists to deepen their understanding of disease mechanisms by studying a disease from several angles, such as the secretome, metabolome, and phosphoproteome. Unfortunately, many scientists believe that functional immune research requires a lengthy workflow with many expensive technologies and specialized personnel to run them, even to look at only one -ome. Researchers might assume that running a multi-omic analysis will take months or years and put a significant strain on their lab's budget.

Because immune cells communicate via cytokines, it is crucial to capture the range of relevant cytokines to understand disease mechanisms and develop effective therapeutics. The ability to conduct functional proteomics on the single-cell level is also vital, as cells are heterogeneous. Traditional technologies such as mass spectrometry, genomics, and flow cytometry are missing a critical data layer for accelerating curative medicines. Further, when it comes to treating solid tumors, signaling and activation pathways are key to understanding how tumors become resistant, but current technologies fall short in providing crucial data to solve this challenge. 

IsoPlexis' single-cell secreted proteomics unlocks a new functional data layer by detecting rare cell subsets of highly polyfunctional cells, which have been proven to be highly predictive biomarkers in studies across many different research disciplines. Polyfunctionality has correlated with outcomes, such as in vivo persistence, anti-tumor function, and immune suppression in several high-impact publications. This technology has been crucial in many different areas, but cancer presents a unique set of challenges that IsoPlexis can solve. When cells begin to become drug-tolerant, they undergo metabolic changes, where phosphorylated protein signaling plays a large role. Combining single-cell phosphoproteomics with metabolomics allows for the characterization of phosphoprotein signaling cascades, activation pathways, and cellular metabolism so that resistant cell populations and functional pathways to resistance can be identified and resolved. IsoPlexis' single-cell phosphoproteomics and metabolomics accelerates the discovery of biomarkers of drug resistance and the development of therapeutics for difficult-to-treat tumors.

Across a broad range of medical disciplines, IsoPlexis' multifaceted functional proteomics platform enables biomarker discovery with single-cell secreted proteomics, low-volume highly multiplexed proteomics from serum, single-cell phosphoprotein analysis, and single-cell metabolomic analysis all on one integrated, benchtop system, making multi-omic analysis accessible to virtually every lab worldwide. By providing walk-away automation and returning fully analyzed, publication-ready data same-day with the powerful IsoSpeak data informatics software, researchers can conduct a multi-omic workflow in just one week, saving valuable time.

Learn more about IsoPlexis technology, download our eBook: Accelerating Clinical Biomarker Discovery for Curative Medicines.

About the Sponsor
  • IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in-vivo biology and develop more precise and personalized therapies.
You May Also Like
DEC 22, 2021
Microbiology
Some Gut Bacteria Produce Toxic Chemicals That Can Damage the Brain
DEC 22, 2021
Some Gut Bacteria Produce Toxic Chemicals That Can Damage the Brain
Gut bacteria perform some essential functions. They help us digest certain foods and absorb nutrients. The community of ...
DEC 27, 2021
Health & Medicine
PFAS Found Entering the Atmosphere via Sea Spray
DEC 27, 2021
PFAS Found Entering the Atmosphere via Sea Spray
Per- and polyfluoroalkyl substances (PFAS) have been in the news recently. The United States Environmental Protection Ag ...
JAN 01, 2022
Health & Medicine
Novavax's More Traditional COVID-19 Vaccine Gets Approval From European Commission and World Health Organization
JAN 01, 2022
Novavax's More Traditional COVID-19 Vaccine Gets Approval From European Commission and World Health Organization
Novavax, a Maryland-based biotechnology company, gets approval for its more traditional protein-subunit COVID-19 vaccine ...
JAN 05, 2022
Technology
A Digital Therapeutic for IBS Pain Management?
JAN 05, 2022
A Digital Therapeutic for IBS Pain Management?
Digital therapeutics (DTx) continue to rise in prevalence and scientific efficacy. While technology is nothing new in he ...
JAN 07, 2022
Drug Discovery & Development
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
JAN 07, 2022
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial o ...
JAN 13, 2022
Cardiology
Extreme Exercise and Heart Disease Risk
JAN 13, 2022
Extreme Exercise and Heart Disease Risk
Marathons and HIIT workouts are more popular than ever. But how do they impact the heart?
Loading Comments...